Enalapril Articles
Recordati's first-half net income jumps 16.7%
18 August 2008
Recordati's first-half net income jumps 16.7%
18 August 2008
Merck & Co sells JV products to AZ
10 March 2008
Bently gets Spanish OK for five generic drugs
5 November 2007
Bulgarian pharma market grows 18.5%
4 June 2007
Strong animal data on NicOx' blood pressure drug
20 November 2006
Concor removes need for pre-op cardiac testing
18 September 2006
India's Ranbaxy on European buying spree
3 April 2006
Merck KGaA's Concor shows good efficacy with novel ACE regimen
12 September 2005
Recordati buys unit of German's Merckle
7 February 2005
Strong 1st-half results for Richter Gedeon
9 August 2004
Grupo Vita denies approach from P&G
1 March 2004
Generics "can be dearer in Canada than USA"
26 January 2004
Grupo Vita and H-Pharm sign agreement for Eneas
20 October 2003
French drugmakers in pricing conundrum
15 September 2003
Finnish generic law saves 5.3 M euros since April
16 June 2003
Fournier to sell Eneas in Turkey
2 June 2003
Pliva closes deal to acquire Spain's Edigen
7 April 2003
Merck & Co hits impasse in Richter patent dispute
3 March 2003
Generic drug sales take off in Brazil
3 March 2003
Pliva to buy generics firm in Spain
17 February 2003
Richter wins enalapril case in Hungary
17 February 2003
Francisco Durban moving into generics
5 August 2002
Biovail increases 2002 revenue guidance
27 May 2002
Pharmacia's eplerenone better in combination
1 April 2002
Bristol-Myers Squibb slumps as Vanlev data disappoints
25 March 2002
Stock Commentary - New York
25 March 2002
Spain's Grupo Vita gains ENEAS appro
11 February 2002
Five key products continue to drive Merck & Co sales in 2001
28 January 2002
Hypertension market prospects to 2010
13 December 2001
Stock Commentary - New York
25 October 2001
Merck & Co turnover up 13% but Vioxx sales are slowing down
19 October 2001
B-MS to re-file Vanlev NDA by year-end
26 September 2001
B-MS to re-file Vanlev NDA by year-end
25 September 2001
Generic flutamide reaches US market
20 September 2001
Japan pharma stocks - week to July 23
25 July 2001
PhRMA R&D spending claims attacked
25 July 2001
Vita completes final analysis of Ph III trials
18 June 2001
Nu-lotan driving sales at Banyu
8 June 2001
B-MS to delay Vanlev refiling with FDA
17 May 2001
Merck & Co sales leap 28%; EPS up 13%
23 April 2001
Grupo Vita gears up for antihypertensive approval
15 March 2001
B-MS completes enrollment in OCTAVE study
23 January 2001
B-MS begins enrollment in new Vanlev study
25 September 2000
Spanish drugmakers adapt to advent of generics regime
15 September 2000
Ranbaxy cardiac drug launch in USA sees brisk sales
7 September 2000
Indian firms to launch new drugs this fiscal year
29 August 2000
Merck & Co posts strong sales growth
25 July 2000
B-MS to begin Vanlev trial vs enalapril
20 July 2000
Stock Commentary New York
17 February 2000
Merck gets extended marketing exclusivity for Vasotec
10 February 2000
Banyu results strong despite Lipovas decline
24 November 1999
B-MS to file for Vanlev approval by year-end
11 November 1999
Novartis starts Lotrel/Innovace comparison trial
10 November 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
Generic approvals for Norton in UK
1 July 1999
Richter Gideon in face-off with MSD
17 May 1999
Swedish pharma market sees 16.2% growth for 1998, says LIF
12 February 1999
Beyond ACE inhibition: the future of angiotensin I inhibitors
11 February 1999
Candesartan trial shows benefits in women
4 February 1999
Merck disappointment as highly-touted antidepressant stalls
26 January 1999
Amlodipine Cuts Cardiac Events In CAD Patients
18 November 1998
Japanese Firms Report Disappointing Figures
18 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Generics Set To Boom From Off-Patent Blockbusters
13 October 1998
US Drug Stocks Plummet After Merck Disappoints
23 July 1998
Roche's Bosentan, Hypertension Data
19 March 1998
Calcium Channel Blocker Link To Suicide
11 March 1998
HMR Launches Teczem In USA
19 February 1998
New Products Provide Boost To Richter Gideon Profits
18 February 1998
Highlights Of Astra's Pipeline Presentation
30 January 1998
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
3rd-Qtr Rx Drug Prices Up 2.9%, Generics Fall 6.4%
25 November 1997
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
